AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Vanda Pharmaceuticals Inc... (VNDA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.50

-0.05 (-1.10%)

At close: Feb 20, 2025, 3:59 PM

4.49

-0.33%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	4.35
Market Cap	262.71M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.33
PE Ratio (ttm)	-13.65
Forward PE	n/a
Analyst	Strong Buy

Ask	4.66
Volume	421,795
Avg. Volume (20D)	637,591
Open	4.54
Previous Close	4.55
Day's Range	4.45 - 4.59
52-Week Range	3.71 - 6.75
Beta	undefined

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatr...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 12, 2006

Employees 368

Stock Exchange NASDAQ

Ticker Symbol VNDA

Website https://www.vandapharma.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for VNDA stock is "Strong Buy." The 12-month stock price forecast is $16.5, which is an increase of 266.26% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Vanda Pharmaceuticals Inc. is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

+8.33%

Vanda Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription

7 months ago

-2.84%

Vanda Pharmaceuticals Inc. shares are trading lower after Future Pak withdrew its proposal to purchase the company.

News

1 week ago · seekingalpha.com

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, Presid...

1 week ago · zacks.com

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.

1 month ago · zacks.com

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.

1 month ago · youtube.com

Nvidia stock inflows reach $30B: Vanda Research

Retail investors flocked to Nvidia (NVDA) in 2024. According to Vanda Research, the chip giant saw nearly $30 billion in inflows during the year.

1 month ago · zacks.com

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.

2 months ago · seekingalpha.com

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Vanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt and PONVORY distribution. I'm interested in buying the stock prior to FY 2024 resul...

2 months ago · businesswire.com

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors' and officers' possible...